<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178059</url>
  </required_header>
  <id_info>
    <org_study_id>D4711C00002</org_study_id>
    <nct_id>NCT02178059</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2</brief_title>
  <official_title>An Open-label, Single-dose, 2-period Cross Over Study in Healthy Volunteers to Assess Relative Bioavailability of Terbutaline Sulphate 1.5 mg After Inhalation Via the M3 Turbuhaler Compared With the M2 Turbuhaler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relative bioavailability study to compare inhalation of Terbutaline Sulphate 1,5mg via
      current version of Turbuhaler with inhalation via a new version
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Single-dose, 2-period Cross over Study in Healthy Male and Female Volunteers
      to Assess Relative Bioavailability of Terbutaline Sulphate 1.5 mg after Inhalation via the M3
      Turbuhaler (New Version) Compared with the M2 Turbuhaler (Current Version)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)]</measure>
    <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
    <description>These will be taken at each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
    <description>These will be taken at each treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
    <description>These will be taken at each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC)</measure>
    <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
    <description>These will be taken at each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero to 36 Hours Postdose [AUC(0-36)]</measure>
    <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
    <description>These will be taken at each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2)</measure>
    <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
    <description>These will be taken at each treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Bricanyl Turbuhaler M3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bricanyl Turbuhaler M2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbutaline sulphate delivered dose</intervention_name>
    <description>0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
    <arm_group_label>Bricanyl Turbuhaler M3</arm_group_label>
    <other_name>Turbuhaler New Version</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbutaline sulphate metered dose</intervention_name>
    <description>0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
    <arm_group_label>Bricanyl Turbuhaler M2</arm_group_label>
    <other_name>Turbuhaler Current Version</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female and male volunteers aged between 18 and 65 years, both inclusive

          2. Healthy as judged by the Principal Investigator after medical history, physical
             examination, 12-lead ECG, laboratory tests (including HIV, HBsAg and hepatitis C
             antibody tests) and assessments of pulse rate and blood pressure

          3. Ability to use a Turbuhaler according to the provided instructions, as judged by the
             Principal Investigator or the study nurse

          4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weighing at least
             50 kg and no more than 100 kg -

        Exclusion Criteria:

          1. History or presence of respiratory, gastrointestinal, hepatic or renal disease or any
             other condition known to interfere with absorption, distribution, metabolism or
             excretion of drugs (except for cholecystectomy)

          2. Current smokers or those who have smoked or used nicotine products within the previous
             3 months should be excluded

          3. Plasma donation within 1 month of screening or any blood donation or blood loss of
             more than 500 mL during the 3 months prior to screening

          4. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the Principal Investigator or history of hypersensitivity to terbutaline (or
             drugs of a similar chemical structure or class) or inhaled lactose

          5. Positive screen for drugs of abuse and/or alcohol and/or cotinine at screening (Visit
             1) or on admission to the study centre (Day -1) prior to administration of the
             investigational medical product (IMP) on Day 1 -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amitava Ganguli, MB ChB, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles London United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Göran Eckervall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ola Beckman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Astrazeneca Mölndal, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <results_first_submitted>November 5, 2015</results_first_submitted>
  <results_first_submitted_qc>June 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2016</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers, pharmacokinetic, inhalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single centre study conducted in the UK.</recruitment_details>
      <pre_assignment_details>Healthy subjects were assessed for eligibility at a screening visit (Visit 1) within 28 days of administration of the first dose of terbutaline via Bricanyl Turbuhaler M2 or Bricanyl Turbuhaler M3 (Visit 2). Subjects were randomly assigned to 1 of 2 treatment sequences: M3 then M2 or M2 then M3</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>M3 First, Then M2</title>
          <description>Sequence 1: M3 first then M2</description>
        </group>
        <group group_id="P2">
          <title>M2 First, Then M3</title>
          <description>Sequence 2: M2 first, then M3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Randomized Subjects</title>
          <description>All randomized subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)]</title>
        <description>These will be taken at each treatment period</description>
        <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
        <population>The PK analysis set included all healthy subjects who received at least 1 dose of the IMP and had at least 1 postdose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Bricanyl Turbuhaler M3</title>
            <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
          </group>
          <group group_id="O2">
            <title>Bricanyl Turbuhaler M2</title>
            <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)]</title>
          <description>These will be taken at each treatment period</description>
          <population>The PK analysis set included all healthy subjects who received at least 1 dose of the IMP and had at least 1 postdose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of the IMP.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.04" lower_limit="80.84" upper_limit="98.07"/>
                    <measurement group_id="O2" value="100.9" lower_limit="91.54" upper_limit="111.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No increase in the exposure of plasma terbutaline after administration of Bricanyl Turbuhaler M3 will be concluded if the upper bound of the 90% CIs for the ratios of AUC and Cmax are both below 1.25</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Approximately 34 healthy volunteers will be entered into the study in order to complete 30 evaluable volunteers. Based on the study SD-001-0268, a residual intra-individual standard deviation of 0.300/sqrt(2) = 0.212 can be expected on the natural log scale. With 30 completed volunteers there will be a 93% chance that the upper limits of two-sided 90% CI for Cmax and AUC ratios are &lt;1.25 provided that the true mean ratios are &lt;1.05.</non_inferiority_desc>
            <param_type>Ratio of geometric means (%)</param_type>
            <param_value>88.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.03</ci_lower_limit>
            <ci_upper_limit>96.02</ci_upper_limit>
            <estimate_desc>Comparison of Bricanyl Turbuhaler M3 (test) to Bricanyl Turbuhaler M2 (reference)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <description>These will be taken at each treatment period</description>
        <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bricanyl Turbuhaler M3</title>
            <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
          </group>
          <group group_id="O2">
            <title>Bricanyl Turbuhaler M2</title>
            <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <description>These will be taken at each treatment period</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.33" upper_limit="1.67"/>
                    <measurement group_id="O2" value="1.33" lower_limit="1.33" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8052</p_value>
            <method>Wilcoxon signed rank test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC)</title>
        <description>These will be taken at each treatment period</description>
        <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bricanyl Turbuhaler M3</title>
            <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
          </group>
          <group group_id="O2">
            <title>Bricanyl Turbuhaler M2</title>
            <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC)</title>
          <description>These will be taken at each treatment period</description>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.63" lower_limit="87.68" upper_limit="106.5"/>
                    <measurement group_id="O2" value="109.7" lower_limit="99.43" upper_limit="121.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero to 36 Hours Postdose [AUC(0-36)]</title>
        <description>These will be taken at each treatment period</description>
        <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bricanyl Turbuhaler M3</title>
            <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
          </group>
          <group group_id="O2">
            <title>Bricanyl Turbuhaler M2</title>
            <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero to 36 Hours Postdose [AUC(0-36)]</title>
          <description>These will be taken at each treatment period</description>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" spread="29.5"/>
                    <measurement group_id="O2" value="101" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2)</title>
        <description>These will be taken at each treatment period</description>
        <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bricanyl Turbuhaler M3</title>
            <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
          </group>
          <group group_id="O2">
            <title>Bricanyl Turbuhaler M2</title>
            <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2)</title>
          <description>These will be taken at each treatment period</description>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="8.9"/>
                    <measurement group_id="O2" value="11.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>These will be taken at each treatment period</description>
        <time_frame>Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose</time_frame>
        <population>The PK analysis set included all healthy subjects who received at least 1 dose of the IMP and had at least 1 postdose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Bricanyl Turbuhaler M3</title>
            <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
          </group>
          <group group_id="O2">
            <title>Bricanyl Turbuhaler M2</title>
            <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>These will be taken at each treatment period</description>
          <population>The PK analysis set included all healthy subjects who received at least 1 dose of the IMP and had at least 1 postdose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of the IMP.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" lower_limit="10.73" upper_limit="13.40"/>
                    <measurement group_id="O2" value="13.12" lower_limit="11.73" upper_limit="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No increase in the exposure of plasma terbutaline after administration of Bricanyl Turbuhaler M3 will be concluded if the upper bound of the 90% CIs for the ratios of AUC and Cmax are both below 1.25</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Approximately 34 healthy volunteers will be entered into the study in order to complete 30 evaluable volunteers. Based on the study SD-001-0268, a residual intra-individual standard deviation of 0.300/sqrt(2) = 0.212 can be expected on the natural log scale. With 30 completed volunteers there will be a 93% chance that the upper limits of two-sided 90% CI for Cmax and AUC ratios are &lt;1.25 provided that the true mean ratios are &lt;1.05.</non_inferiority_desc>
            <param_type>Ratio of geometric means (%)</param_type>
            <param_value>91.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.82</ci_lower_limit>
            <ci_upper_limit>98.58</ci_upper_limit>
            <estimate_desc>Comparison of Bricanyl Turbuhaler M3 (test) to Bricanyl Turbuhaler M2 (reference)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bricanyl Turbuhaler M3</title>
          <description>Bricanyl Turbuhaler M3: 0.4 mg terbutaline sulphate (delivered dose) per inhalation</description>
        </group>
        <group group_id="E2">
          <title>Bricanyl Turbuhaler M2</title>
          <description>Bricanyl Turbuhaler M2: 0.5 mg terbutaline sulphate (metered dose) per inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Göran Eckerwall, Medical Science Director</name_or_title>
      <organization>AstraZeneca R&amp;D</organization>
      <phone>1-800-236-9933</phone>
      <email>Goran.Eckerwall@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

